Back to GILDView Full Landscape
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
15 competitors in Type 2 Diabetes Mellitus
LLYInsulin Peglispro
Phase 3LLYDulaglutide
Phase 3AZNexenatide twice daily
Phase 3LLYInsulin Lispro
Phase 3LLYInsulin Degludec
Phase 3Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA7/8/2008
Ranexa (previously Latixa)
Ranexa is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti-anginal therapies (such as beta-blockers and / or calcium antagonists).
View on EMADrug Science
Mechanism of action & safety profile
Developer
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts